​
​

Supernus Pharmaceuticals (SUPN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Supernus Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$607.52M

Latest Revenue (Q)

$175.69M

Main Segment (Y)

Product

Supernus Pharmaceuticals Revenue by Period

Supernus Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$607.52M-8.95%
2022-12-31$667.24M15.09%
2021-12-31$579.77M11.41%
2020-12-31$520.40M32.50%
2019-12-31$392.75M-3.95%
2018-12-31$408.90M35.29%
2017-12-31$302.24M40.57%
2016-12-31$215.00M48.87%
2015-12-31$144.43M18.34%
2014-12-31$122.05M915.43%
2013-12-31$12.02M712.09%
2012-12-31$1.48M84.31%
2011-12-31$803.00K657.55%
2010-12-31$106.00K-99.72%
2009-12-31$37.92M326.65%
2008-12-31$8.89M109.97%
2007-12-31$4.23M-

Supernus Pharmaceuticals generated $607.52M in revenue during NA 2023, up -8.95% compared to the previous quarter, and up 148.58% compared to the same period a year ago.

Supernus Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-09-30$175.69M4.37%
2024-06-30$168.32M17.18%
2024-03-31$143.64M-12.58%
2023-12-31$164.31M6.78%
2023-09-30$153.88M13.51%
2023-06-30$135.56M-11.84%
2023-03-31$153.76M-8.11%
2022-12-31$167.33M-5.65%
2022-09-30$177.35M4.29%
2022-06-30$170.05M11.50%
2022-03-31$152.51M-4.11%
2021-12-31$159.05M7.13%
2021-09-30$148.46M5.05%
2021-06-30$141.33M7.94%
2021-03-31$130.93M-8.79%
2020-12-31$143.56M-7.46%
2020-09-30$155.13M22.41%
2020-06-30$126.73M33.43%
2020-03-31$94.98M-5.45%
2019-12-31$100.45M-1.66%
2019-09-30$102.14M-2.44%
2019-06-30$104.69M22.49%
2019-03-31$85.47M-26.27%
2018-12-31$115.93M12.56%
2018-09-30$103.00M3.47%
2018-06-30$99.54M10.07%
2018-03-31$90.43M2.25%
2017-12-31$88.44M10.00%
2017-09-30$80.40M6.03%
2017-06-30$75.83M31.70%
2017-03-31$57.58M-7.69%
2016-12-31$62.37M9.79%
2016-09-30$56.81M12.67%
2016-06-30$50.42M17.05%
2016-03-31$43.08M0.98%
2015-12-31$42.66M10.55%
2015-09-30$38.59M10.08%
2015-06-30$35.05M24.59%
2015-03-31$28.13M-8.66%
2014-12-31$30.80M-41.32%
2014-09-30$52.49M76.88%
2014-06-30$29.68M226.78%
2014-03-31$9.08M-12.13%
2013-12-31$10.34M722.20%
2013-09-30$1.26M347.33%
2013-06-30$281.00K91.16%
2013-03-31$147.00K-86.50%
2012-12-31$1.09M1096.70%
2012-09-30$91.00K-
2012-06-30$91.00K-56.25%
2012-03-31$208.00K-102.11%
2011-12-31$-9.85M-89600.00%
2011-09-30$11.00K-98.53%
2011-06-30$750.00K100.00%
2011-03-31--100.00%
2010-12-31$-8.63M67.83%
2009-12-31$-5.14M-

Supernus Pharmaceuticals generated $175.69M in revenue during Q3 2024, up 4.37% compared to the previous quarter, and up 129.60% compared to the same period a year ago.

Supernus Pharmaceuticals Revenue Breakdown

Supernus Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Oxtellar X R$113.40M$115.34M$110.71M$98.72M$88.19M
Manufactured Product, Other$31.28M$31.82M---
GOCOVRI$119.64M$104.42M$9.78M--
APOKYN$75.08M$75.31M$99.23M$74.30M-
Trokendi Xr$94.34M$261.22M$304.82M$319.64M$295.21M
Royalty$33.59M$17.81M$12.27M$11.05M$9.36M
Qelbree$140.19M$61.32M$9.88M--
Product$573.93M$649.43M$567.50M$509.35M$383.40M
XADAGO--$13.39M$6.94M-
MYOBLOC--$19.51M$9.75M-
Osomolex ER--$188.00K--
License-----

Supernus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (48.58%), Qelbree (11.87%), GOCOVRI (10.13%), Oxtellar X R (9.60%), Trokendi Xr (7.98%), APOKYN (6.36%), Royalty (2.84%), and Manufactured Product, Other (2.65%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
APOKYN$19.87M$16.65M$18.76M$21.51M$17.61M$17.21M$18.15M$18.26M$20.45M$18.45M$25.89M$24.63M$26.98M$21.73M$31.21M$34.48M$8.60M---
Trokendi Xr$15.32M$15.99M$19.60M$20.63M$19.32M$34.79M$57.19M$69.60M$71.60M$62.83M$73.29M$80.94M$78.78M$71.82M$78.51M$82.91M$89.67M$75.22M$77.33M-
Royalty, License And Other Revenue$5.39M-------------------
Qelbree$62.36M$45.10M$46.35M$37.08M$30.98M$25.78M$23.61M$18.33M$11.10M$8.28M$7.19M$2.37M$315.00K-------
Product$170.30M$138.46M$156.02M$149.00M$128.34M$140.57M$163.78M$172.72M$165.46M$147.46M$154.96M$145.53M$138.63M$128.38M$140.74M$152.13M$123.98M$92.49M$97.91M$100.03M
Oxtellar X R$29.80M$26.94M$31.05M$29.64M$23.80M$28.91M$27.34M$30.53M$29.96M$27.52M$28.59M$29.73M$25.02M$27.37M$22.74M$28.36M$23.68M$23.94M$22.68M$22.70M
Manufactured Product, Other$7.30M$7.21M$8.27M$7.25M$7.88M$7.87M$8.25M$8.13M$7.65M$7.78M----------
GOCOVRI$35.66M$26.56M$31.99M$32.89M$28.75M$26.01M$29.24M$27.88M$24.70M$22.60M----------
Royalty And License-$5.18M------------------
Royalty--$8.30M$4.88M$7.23M$13.19M$3.54M$4.63M$4.59M$5.04M$4.09M$2.93M$2.70M$2.55M$2.81M$3.00M$2.75M$2.49M$2.54M$2.11M
MYOBLOC----------$6.04M$4.60M$4.64M$4.24M$4.47M$4.05M$1.23M---
XADAGO----------$4.00M$3.28M$2.89M$3.22M$3.81M$2.33M$801.00K---
License--------------------

Supernus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (49.22%), Qelbree (18.02%), GOCOVRI (10.31%), Oxtellar X R (8.61%), APOKYN (5.74%), Trokendi Xr (4.43%), Manufactured Product, Other (2.11%), and Royalty, License And Other Revenue (1.56%).

Supernus Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
PBHPrestige Consumer Healthcare$1.13B$283.55M
PAHCPhibro Animal Health$977.89M$273.16M
EVOEvotec SE$781.43M$208.73M
PCRXPacira BioSciences$674.98M$168.57M
SUPNSupernus Pharmaceuticals$607.52M$175.69M
COLLCollegium Pharmaceutical$566.77M$159.30M
ANIPANI Pharmaceuticals$486.82M$148.33M
EGRXEagle Pharmaceuticals$316.61M$64.65M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
SSICSilver Spike Investment$11.72M$2.76B
RGCRegencell Bioscience--

SUPN Revenue FAQ

What is Supernus Pharmaceuticals’s yearly revenue?

Supernus Pharmaceuticals's yearly revenue for 2023 was $607.52M, representing a decrease of -8.95% compared to 2022. The company's yearly revenue for 2022 was $667.24M, representing an increase of 15.09% compared to 2021. SUPN's yearly revenue for 2021 was $579.78M, representing an increase of 11.41% compared to 2020.

What is Supernus Pharmaceuticals’s quarterly revenue?

Supernus Pharmaceuticals's quarterly revenue for Q3 2024 was $175.69M, a 4.37% increase from the previous quarter (Q2 2024), and a 14.17% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $168.32M, a 17.18% increase from the previous quarter (Q1 2024), and a 24.17% increase year-over-year (Q2 2023). SUPN's quarterly revenue for Q1 2024 was $143.64M, a -12.58% decrease from the previous quarter (Q4 2023), and a -6.58% decrease year-over-year (Q1 2023).

What is Supernus Pharmaceuticals’s revenue growth rate?

Supernus Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 4.79%, and for the last 5 years (2019-2023) was 54.68%.

What are Supernus Pharmaceuticals’s revenue streams?

Supernus Pharmaceuticals's revenue streams in c 23 are Oxtellar X R, Manufactured Product, Other, GOCOVRI, APOKYN, Trokendi Xr, Royalty, Qelbree, and Product. Oxtellar X R generated $113.4M in revenue, accounting 9.60% of the company's total revenue, down -1.68% year-over-year. Manufactured Product, Other generated $31.28M in revenue, accounting 2.65% of the company's total revenue, down -1.69% year-over-year. GOCOVRI generated $119.64M in revenue, accounting 10.13% of the company's total revenue, up 14.57% year-over-year. APOKYN generated $75.08M in revenue, accounting 6.36% of the company's total revenue, down -0.29% year-over-year. Trokendi Xr generated $94.34M in revenue, accounting 7.98% of the company's total revenue, down -63.89% year-over-year. Royalty generated $33.59M in revenue, accounting 2.84% of the company's total revenue, up 88.63% year-over-year. Qelbree generated $140.19M in revenue, accounting 11.87% of the company's total revenue, up 128.62% year-over-year. Product generated $573.93M in revenue, accounting 48.58% of the company's total revenue, down -11.63% year-over-year.

What is Supernus Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Supernus Pharmaceuticals was Product. This segment made a revenue of $573.93M, representing 48.58% of the company's total revenue.